Test Helps Clinicians Select Appropriate Tx for Suspected Wound Infections

The test uses DNA-based technology
The test uses DNA-based technology

CogenDx announced the availability of a DxWound, a new DNA-based test that accurately detects a range of aerobic/anaerobic bacteria, fungi, and antibiotic resistance genes. The results from this test can help clinicians quickly identify potential pathogens and choose appropriate antibiotics that may be more likely to clear the infection.

Using a simple swab from the infection site, DxWound uses a special transport buffer that preserves the wound microbiome during transit. The transport solution "freezes" wound microbiome at the time of collection and kills the microbes while preserving the DNA. The test provides sensitive detection of pathogens most commonly associated with skin and soft tissue infections (SSTI) and genes associated with resistance to commonly used antibiotics. Antibiotic-resistant microbes such as methicillin-resistant Staphylococcus aureus (MRSA) are also analyzed by DxWound. 

Related Articles

Test results are usually available the next business day upon specimen receipt at the laboratory. With the comprehensive report, clinicians are able to select appropriate antibiotic therapy, plan de-escalation or narrow broad spectrum therapy, determine therapy for suspected polymicrobial infections, identify potential antibiotic resistance, and evaluate options for stagnant, and non-healing wounds. 

For more information call (877) 866-0603 or visit CogenDx.com.